The authors describe a patient in whom the serum levels of interleukin-6 (IL-6) and other laboratory parameters were monitored. The IL-6 and C-reac tive protein (CRP) levels, which were extremely high before treatment, declined rapidly with administration of prednisolone. Rheumatoid factor, IgG, and platelets count declined more gradually. Thus, determination of the serum IL-6 level might be useful in diagnosing and monitoring polyarteritis nodosa.
Get full access to this article
View all access options for this article.
References
1.
Kurland LT, Chuang TY, Hunder GG: The epidemiology of systemic arteritis. In: Current Topics in Rheumatology: Epidemiology of the Rheumatic Disease. ed. by Laurence RE, Shulman LE.New York: Gower Medical, 1984.
2.
Wolff SM: Polyarteritis nodosa group. In: Cecil Textbook of Medicine , ed. by Wyngaarden JB, Smith LH Jr.Philadelphia: WB Saunders Company, 1988, pp. 2028-2030.
3.
Fort JG, Abruzzo JL: Reversal of progressive necrotizing vasculitis with intravenous pulse cyclophosphamide and methylprednisolone. Arthritis Rheum31:1194-11981988.
4.
Matsuda T., Hirano T., Kishimoto T.: Establishment of an interleukin (IL6)/B cell stimulatory factor 2-dependent cell line and preparation of anti-IL6 monoclonal antibodies. Eur J Immunol18:651-956, 1988.
5.
Hirano T., Yasukawa K., Harada H., et al: Complementary DNA for a novel human interleukin (BSF-2) that induces B lyphocytes to produce immunoglobulin. Nature324:73-76, 1980.
6.
Lotz M., Jirik F., Kaboridis R., et al: BSF-2/IL-6 is a costimulant for human thymocytes and T lymphocytes . J Exp Med167:1253-1256, 1988 .
7.
Gauldie J., Richards C., Harnigh D., et al: Interferon beta-2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein in liver cells. Proc Natl Acad Sci USA84:7251-7255, 1987.
8.
Koshimoto T. , Hirano T.: Molecular regulation of B lymphocyte response . Ann Rev Immunol6:485-512, 1988.
9.
Nishimoto N. , Yoshizaki K., Tagoh H., et al: Elevation of serum interleukin-6 prior to acute phase proteins on the inflammation by surgical operation. Clin Immunol Immunopathol50:399-401, 1989.
10.
Yoshizaki K. , Matsuda T., Nishimoto N., et al: Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood74:1360-1367, 1989 .
11.
Hirano T., Tata T., Yasukawa K., et al: Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in antibody production. Proc Natl Acad Sci USA84:228-231, 1987.
12.
Nijsten Mwn , Degroot ER, TenDuis HJ, et al: Serum levels of interleukin-6 and acute phase responses. Lancet2:921, 1987.
13.
VanOers MHJ, Van Der Heyden AAPAM, Aarden LA: Interleukin-6 (IL-6) in serum and urine of renal transplant recipients. Clin Exp Immunol71:314-319, 1988.
14.
Hirano T., Matsuda T., Turner M., et al: Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol18:1797-1801, 1988.
15.
Asano S., Okano A., Ozawa K., et al: In vivo effects of recombinant interleukin-6 in primates: Stimulated production of platelets. Blood75:1602-1605, 1990.
